Abstract
The purposes of this project are to enhance the trans-membrane penetration of Δ8-Tetrahydrocannabinol (Δ8-THC) and to study the effect of various lipid based systems in delivering the compound, non-invasively, to anterior and posterior ocular chambers. Solid lipid nanoparticles (SLNs), fast gelling films were manufactured using high pressure homogenization and melt cast techniques, respectively. The formulations were characterized for drug content, entrapment efficiency, particle size and subsequently evaluated in vitro for trans-corneal permeation. In vivo, the drug disposition was tested via topical administration in albino rabbits. The eye globes were enucleated at the end of experiment and tissues were analyzed for drug content. All formulations showed favorable physicochemical characteristics in terms of particle size, entrapment efficiency, and drug content. In vitro, the formulations exhibited a transcorneal flux that depended on the formulation’s drug load. An increase in drug load from 0.1 to 0.75% resulted in 12- to16-folds increase in permeation. In vivo, the film was able to deliver THC to all the tissues with high accumulations in cornea and sclera. The SLNs showed a greater ability in delivering THC to all the tissues, at a significantly lower drug load, due to their colloidal size range, which in turn enhanced corneal epithelial membrane penetration. The topical formulations evaluated in the present study were able to successfully deliver Δ8-THC in therapeutically meaningful concentrations (EC50 values for CB1: 6 nM and CB2: 0.4 nM) to all ocular tissues except the vitreous humor, with pronounced tissue penetration achieved using SLNs as a Δ8-THC delivery vehicle.
Similar content being viewed by others
References
Quigley HA, Nickells RW, Kerrigan LA, Pease ME, Thibault DJ, Zack DJ. Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. Invest Ophthalmol Vis Sci. 1995;36:774–86.
Vasudevan SK, Gupta V, Crowston JG. Neuroprotection in glaucoma. Indian J Ophthalmol. 2011;59 Suppl:S102–13.
Phelps CD, Corbett JJ. Migraine and low-tension glaucoma. A case–control study. Invest Ophthalmol Vis Sci. 1985;26:1105–8.
Rein DB, Zhang P, Wirth KE, Lee PP, Hoerger TJ, McCall N, et al. The economic burden of major adult visual disorders in the United States. Arch Ophthalmol. 2006;124:1754–60.
Ji J, Chang P, Pennesi ME, Yang Z, Zhang J, Li D, et al. Effects of elevated intraocular pressure on mouse retinal ganglion cells. Vision Res. 2005;45:169–79.
Levkovitch-Verbin H, Quigley HA, Martin KR, Valenta D, Baumrind LA, Pease ME. Translimbal laser photocoagulation to the trabecular meshwork as a model of glaucoma in rats. Invest Ophthalmol Vis Sci. 2002;43:402–10.
Leske MC, Wu SY, Honkanen R, Nemesure B, Schachat A, Hyman L, et al. Nine-year incidence of open-angle glaucoma in the Barbados Eye Studies. Ophthalmology. 2007;114:1058–64.
Almasieh M, Wilson AM, Morquette B, Cueva Vargas JL, Di Polo A. The molecular basis of retinal ganglion cell death in glaucoma. Prog Retin Eye Res. 2012;31:152–81.
Bien A, Seidenbecher CI, Bockers TM, Sabel BA, Kreutz MR. Apoptotic versus necrotic characteristics of retinal ganglion cell death after partial optic nerve injury. J Neurotrauma. 1999;16:153–63.
Crandall J, Matragoon S, Khalifa YM, Borlongan C, Tsai NT, Caldwell RB, et al. Neuroprotective and intraocular pressure-lowering effects of (−)Delta9-tetrahydrocannabinol in a rat model of glaucoma. Ophthalmic Res. 2007;39:69–75.
El-Remessy AB, Khalil IE, Matragoon S, Abou-Mohamed G, Tsai NJ, Roon P, et al. Neuroprotective effect of (−)Delta9-tetrahydrocannabinol and cannabidiol in N-methyl-D-aspartate-induced retinal neurotoxicity: involvement of peroxynitrite. Am J Pathol. 2003;163:1997–2008.
He F, Song ZH. Molecular and cellular changes induced by the activation of CB2 cannabinoid receptors in trabecular meshwork cells. Mol Vis. 2007;13:1348–56.
Njie YF, Qiao Z, Xiao Z, Wang W, Song ZH. N-arachidonylethanolamide-induced increase in aqueous humor outflow facility. Invest Ophthalmol Vis Sci. 2008;49:4528–34.
Porcella A, Maxia C, Gessa GL, Pani L. The human eye expresses high levels of CB1 cannabinoid receptor mRNA and protein. Eur J Neurosci. 2000;12:1123–7.
Hingorani T, Adelli GR, Punyamurthula N, Gul W, Elsohly MA, Repka MA, et al. Ocular disposition of the hemiglutarate ester prodrug of (9)-Tetrahydrocannabinol from various ophthalmic formulations. Pharm Res. 2013;30:2146–56.
Hingorani T, Gul W, Elsohly M, Repka MA, Majumdar S. Effect of ion pairing on in vitro transcorneal permeability of a Delta(9) -tetrahydrocannabinol prodrug: potential in glaucoma therapy. J Pharm Sci. 2012;101:616–26.
Ethan B, Russo FG, editors. The handbook of cannabis therapeutics: from bench to bedside. New York: Haworth Integrative Healing Press; 2006.
Muchtar S, Almog S, Torracca MT, Saettone MF, Benita S. A submicron emulsion as ocular vehicle for delta-8-tetrahydrocannabinol: effect on intraocular pressure in rabbits. Ophthalmic Res. 1992;24:142–9.
Zhang J, Purdon C, Smith E. Solid lipid nanoparticles for topical drug delivery. Am J Drug Deliv. 2006;4:215–20.
Zhou H-Y, Hao J-L, Wang S, Zheng Y, Zhang W-S. Nanoparticles in the ocular drug delivery. Int J Ophthalmol. 2013;6:390–6.
De Campos AM, Sanchez A, Alonso MJ. Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int J Pharm. 2001;224:159–68.
Cavalli R, Gasco MR, Chetoni P, Burgalassi S, Saettone MF. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int J Pharm. 2002;238:241–5.
Yuan X-b, Li H, Yuan Y-b. Preparation of cholesterol-modified chitosan self-aggregated nanoparticles for delivery of drugs to ocular surface. Carbohydr Polym. 2006;65:337–45.
Ibrahim HK, El-Leithy IS, Makky AA. Mucoadhesive nanoparticles as carrier systems for prolonged ocular delivery of gatifloxacin/prednisolone bitherapy. Mol Pharm. 2010;7:576–85.
Hermans K, Van den Plas D, Kerimova S, Carleer R, Adriaensens P, Weyenberg W, et al. Development and characterization of mucoadhesive chitosan films for ophthalmic delivery of cyclosporine A. Int J Pharm. 2014;472:10–9.
Attia MA, Kassem MA, Safwat SM. In vivo performance of [3H]dexamethasone ophthalmic film delivery systems in the rabbit eye. Int J Pharm. 1988;47:21–30.
Hippalgaonkar K, Adelli GR, Repka MA, Majumdar S. Indomethacin-loaded solid lipid nanoparticles for ocular delivery: development, characterization, and in vitro evaluation. J Ocul Pharmacol Ther. 2013;29:216–28.
Thumma S, Majumdar S, ElSohly MA, Gul W, Repka MA. Preformulation studies of a Prodrug of Δ(9)-Tetrahydrocannabinol. AAPS PharmSciTech. 2008;9:982–90.
Flom MC, Adams AJ, Jones RT. Marijuana smoking and reduced pressure in human eyes: drug action or epiphenomenon? Invest Ophthalmol. 1975;14:52–5.
ElSohly MA, Harland EC, Benigni DA, Waller CW. Cannabinoids in glaucoma II: the effect of different cannabinoids on intraocular pressure of the rabbit. Curr Eye Res. 1984;3:841–50.
Jay WM, Green K. Multiple-drop study of topically applied 1% delta 9-tetrahydrocannabinol in human eyes. Arch Ophthalmol. 1983;101:591–3.
Green K, Roth M. Ocular effects of topical administration of delta 9-tetrahydrocannabinol in man. Arch Ophthalmol. 1982;100:265–7.
Meisner D, Pringle J, Mezei M. Liposomal ophthalmic drug delivery. III. Pharmacodynamic and biodisposition studies of atropine. Int J Pharm. 1989;55:105–13.
Hippalgaonkar K, Gul W, ElSohly MA, Repka MA, Majumdar S. Enhanced solubility, stability, and transcorneal permeability of delta-8-tetrahydrocannabinol in the presence of cyclodextrins. AAPS PharmSciTech. 2011;12:723–31.
Bloomfield SE, Miyata T, Dunn MW, Bueser N, Stenzel KH, Rubin AL. Soluble gentamicin ophthalmic inserts as a drug delivery system. Arch Ophthalmol. 1978;96:885–7.
Baeyens V, Kaltsatos V, Boisrame B, Varesio E, Veuthey JL, Fathi M, et al. Optimized release of dexamethasone and gentamicin from a soluble ocular insert for the treatment of external ophthalmic infections. J Control Release. 1998;52:215–20.
Bensinger R, Shin DH, Kass MA, Podos SM, Becker B. Pilocarpine ocular inserts. Invest Ophthalmol. 1976;15:1008–10.
Khurana G, Arora S, Pawar PK. Ocular insert for sustained delivery of gatifloxacin sesquihydrate: preparation and evaluations. Int J Pharm Investig. 2012;2:70–7.
Sankar AKCV, Durga S. Design and evaluation of diclofenac sodium ophthalmic inserts. Acta Pharm Sci. 2006;48:5–10.
Theng JT, Ti SE, Zhou L, Lam KW, Chee SP, Tan D. Pharmacokinetic and toxicity study of an intraocular cyclosporine DDS in the anterior segment of rabbit eyes. Invest Ophthalmol Vis Sci. 2003;44:4895–9.
Calvo P, Vila-Jato JL, Alonso MJ. Comparative in vitro evaluation of several colloidal systems, nanoparticles, nanocapsules, and nanoemulsions, as ocular drug carriers. J Pharm Sci. 1996;85:530–6.
Contreras-Ruiz L, de la Fuente M, Parraga JE, Lopez-Garcia A, Fernandez I, Seijo B, et al. Intracellular trafficking of hyaluronic acid-chitosan oligomer-based nanoparticles in cultured human ocular surface cells. Mol Vis. 2011;17:279–90.
de la Fuente M, Seijo B, Alonso MJ. Novel hyaluronic acid-chitosan nanoparticles for ocular gene therapy. Invest Ophthalmol Vis Sci. 2008;49:2016–24.
Enriquez de Salamanca A, Diebold Y, Calonge M, Garcia-Vazquez C, Callejo S, Vila A, et al. Chitosan nanoparticles as a potential drug delivery system for the ocular surface: toxicity, uptake mechanism and in vivo tolerance. Invest Ophthalmol Vis Sci. 2006;47:1416–25.
Pignatello R, Bucolo C, Ferrara P, Maltese A, Puleo A, Puglisi G. Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur J Pharm Sci. 2002;16:53–61.
Pignatello R, Bucolo C, Spedalieri G, Maltese A, Puglisi G. Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application. Biomaterials. 2002;23:3247–55.
Vega E, Egea MA, Valls O, Espina M, Garcia ML. Flurbiprofen loaded biodegradable nanoparticles for ophtalmic administration. J Pharm Sci. 2006;95:2393–405.
Yuan XB, Yuan YB, Jiang W, Liu J, Tian EJ, Shun HM, et al. Preparation of rapamycin-loaded chitosan/PLA nanoparticles for immunosuppression in corneal transplantation. Int J Pharm. 2008;349:241–8.
Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson NO, Leonova J, et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. 2007;152:1092–101.
Acknowledgments
This publication was made possible by Grant Number P20GM104932 from the National Institute of General Medical Sciences (NIGMS), a component of the National Institutes of Health (NIH).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Punyamurthula, N.S., Adelli, G.R., Gul, W. et al. Ocular Disposition of ∆8-Tetrahydrocannabinol from Various Topical Ophthalmic Formulations. AAPS PharmSciTech 18, 1936–1945 (2017). https://doi.org/10.1208/s12249-016-0672-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1208/s12249-016-0672-2